Form 8-K · Current report
Amgen 8-K, filed Oct 27, 2026
- Filed
- CIK
- 0000318154
- Accession no.
- 0000318154-26-000144
Summary
Amgen appointed David W. Gibbs, former CEO of Yum! Brands, to its board of directors effective October 26, 2026; he will serve on the Audit Committee and the Compensation and Management Development Committee. The appointment brings Amgen's board to 13 directors, 12 of whom are independent.
Key points
- Gibbs was CEO of Yum! Brands from 2020 to September 2025 and has been an advisor to the company since October 2025.
- He has been a director of Under Armour since 2021 and of PepsiCo since 2026.
- Amgen CEO Robert A. Bradway said Gibbs's experience creating direct customer relationships would help inform how the company prepares for future launches.
- Gibbs will receive pro-rated non-employee director compensation and a pro-rated annual restricted stock unit grant under Amgen's director equity incentive program.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
From the filing
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) Election of Directors. On October 26, 2026, the Board of Directors (the “Board”) of Amgen Inc. (the “Company”) appointed David W. Gibbs as a director of the Company, effective immediately. Mr. Gibbs served as Chief Executive Officer of Yum! Brands, Inc., a leading global restaurant company, from 2020 to September 2025 and as a director of Yum! Brands from 2019 to September 2025. Since October 2025, Mr. Gibbs has served as an advisor to Yum! Brands. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.